Cleveland Clinic The New Age of Alzheimer’s Disease Therapeutics 2025

Modern Anti-Amyloid Therapy & Early Alzheimer’s Disease Management

The Cleveland Clinic The New Age of Alzheimer’s Disease Therapeutics 2025 course provides a focused, evidence-based update on the rapidly evolving treatment landscape for Alzheimer’s disease (AD), particularly the integration of anti-amyloid therapies into clinical practice.

With the emergence of disease-modifying anti-amyloid treatments for patients with mild cognitive impairment (MCI) and early-stage Alzheimer’s disease, clinicians face new challenges involving:

• Patient selection
• Cognitive assessment
• MRI monitoring
• ARIA (amyloid-related imaging abnormalities) management
• Infusion logistics
• Insurance authorization
• Long-term treatment planning

This educational program equips healthcare providers with practical tools and clinical strategies to confidently implement anti-amyloid therapies while improving collaboration between neurology and primary care teams for earlier diagnosis and treatment initiation.

---

📦 Product Details

• 🎥 5 Video Lectures
• 🎧 5 Audio Files
• 📝 5 Subtitle Files (.vtt)
• 📄 1 PDF
• 💾 Total Size: 2 GB
• 📅 Year: 2025
• 🌐 Format: On-Demand Conference Recordings
• 🧠 Specialty: Neurology & Cognitive Disorders

---

👨‍⚕️ Target Audience

This course is ideal for:

• Neurologists
• Primary care physicians
• Internists
• Geriatricians
• Nurse practitioners
• Nurses
• Healthcare professionals involved in dementia care

It is especially valuable for clinicians seeking:
✔️ Anti-amyloid therapy implementation guidance
✔️ Alzheimer’s disease treatment updates
✔️ MCI and early dementia management strategies
✔️ ARIA monitoring and safety education
✔️ Practical cognitive care workflows

---

🧠 Program Overview

The approval of anti-amyloid therapies has created a major paradigm shift in Alzheimer’s disease management.

Clinicians now face critical questions regarding:

• Which patients qualify for therapy
• Appropriate cognitive and biomarker evaluation
• MRI surveillance protocols
• ARIA detection and management
• Infusion coordination
• Insurance and authorization logistics
• Treatment duration and monitoring

This course provides practical, clinically relevant education designed to help providers integrate these therapies into real-world practice while improving early detection and multidisciplinary Alzheimer’s care.

---

🎯 Learning Objectives

After completing this program, participants will be able to:

✔️ Describe the clinical effects and benefits of anti-amyloid therapies
✔️ Identify appropriate candidates for anti-amyloid treatment
✔️ Recognize and monitor complications such as ARIA
✔️ Implement cognitive assessment strategies for MCI and early AD
✔️ Navigate insurance and pre-authorization requirements
✔️ Coordinate infusion logistics and treatment workflows
✔️ Improve collaboration between neurologists and primary care providers
✔️ Accelerate recognition and treatment initiation for Alzheimer’s disease patients

---

🧩 Core Topics Covered

🧠 Anti-Amyloid Therapies

• Disease-modifying Alzheimer’s treatments
• Mechanisms of anti-amyloid agents
• Clinical trial outcomes and efficacy
• Practical integration into clinical care

🔬 Mild Cognitive Impairment & Early Alzheimer’s Disease

• Early cognitive assessment
• Screening strategies
• MCI diagnosis and progression risk
• Early-stage AD evaluation

⚠️ ARIA Monitoring & Safety

• Amyloid-related imaging abnormalities (ARIA)
• MRI surveillance protocols
• Risk stratification and patient counseling
• Management of treatment complications

📋 Patient Selection & Eligibility

• Identifying treatment candidates
• Biomarker and imaging considerations
• Clinical inclusion and exclusion criteria
• Shared decision-making approaches

🏥 Infusion Logistics & Care Coordination

• Infusion center workflows
• Treatment scheduling and monitoring
• Interdisciplinary collaboration
• Long-term follow-up strategies

💼 Insurance & Pre-Authorization

• Administrative pathways for therapy approval
• Documentation requirements
• Access and reimbursement considerations

🤝 Neurology & Primary Care Collaboration

• Earlier recognition of cognitive decline
• Referral optimization
• Shared management models
• Integrated dementia care pathways

---

📚 Educational Features

✔️ Practical Clinical Focus

Designed to help clinicians implement anti-amyloid therapies in real-world settings.

✔️ Evidence-Based Alzheimer’s Updates

Reviews current data on disease-modifying Alzheimer’s treatments.

✔️ Safety & Monitoring Education

Strong emphasis on ARIA recognition and management.

✔️ Multidisciplinary Care Integration

Encourages collaboration between neurology and primary care.

✔️ Flexible Learning Resources

Includes videos, audio recordings, subtitles, and PDF materials.

---

⭐ Why This Course Stands Out

✔️ Focused on the New Era of Alzheimer’s Therapy

Addresses one of the most rapidly evolving areas in neurology.

✔️ Strong Real-World Clinical Relevance

Covers practical implementation challenges often omitted from standard CME.

✔️ Comprehensive ARIA & Monitoring Coverage

Provides essential safety management education for anti-amyloid therapies.

✔️ Excellent for Both Specialists & PCPs

Bridges the gap between neurology and frontline cognitive care.

✔️ Highly Practical Workflow Guidance

Includes infusion logistics, authorization, and care coordination strategies.

---

🚀 Clinical Value

The Cleveland Clinic The New Age of Alzheimer’s Disease Therapeutics 2025 provides an essential update for clinicians navigating the rapidly changing treatment landscape of Alzheimer’s disease.

By integrating:

• Anti-amyloid therapies
• Early Alzheimer’s disease diagnosis
• MCI assessment
• ARIA monitoring
• Infusion workflows
• Insurance authorization strategies
• Multidisciplinary cognitive care

the course equips healthcare providers with practical, evidence-based tools to confidently manage modern Alzheimer’s therapeutics and improve patient outcomes.

For neurologists, geriatricians, internists, and primary care clinicians seeking updated guidance on anti-amyloid therapy implementation and early dementia management, this course is a highly valuable educational resource.

+ Topics:

• 01 Background on antiamyloid therapies Charles Bernick, MD, MPH
• 02 Translating clinical trial results to the clinic Babak Tousi, MD
• 03 Who is the right patient for anti-amyloid therapies Lakeshia Gibson, MD
• 04 Surveillance for amyloid-related imaging abnormalities (ARIA) Dylan Wint, MD
• 05 Logistics of starting anti-amyloid therapy Maileen Ulep, PhD, MSN, APRN, FNP-BC